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Abstract 
Short communication on NDUFA13, with data on 
DNA/RNA, on the protein encoded and where this 
gene is implicated. 
Keywords 
NDUFA13; GRIM-19; mitochondria complex I; 
apoptosis. 
Identity 
Other names: B16.6, CDA016, CGI-39, GRIM-19, 
GRIM19, complex I B16.6 subunit 
HGNC (Hugo): NDUFA13 
Location: 19p13.11 (Chromosome 19: 19,626,545-
19,644,285 forward strand.) (Chidambaram et al., 
2000). 
Location (base pair) : Starts at 19515989 and ends 
at 19528126 bp (according to COSMIC) 
Local order: Orientation: Forward Strand. Between 
theGATAD2A and YJEFN3 genes. 
DNA/RNA 
Note 
NDUFA13 is a protein-coding gene, which encodes 
a subunit of the mitochondrial respiratory chain 
NADH dehydrogenase (Complex I). 
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Description 
The NDUFA13 gene, with 18995 bases in length 
(NG_013380), consists 5 exons and 4 introns. It was 
first identified and isolated by antisense knock-out 
techniques, in a study aiming the identification of 
gene products that participate in synergistic growth-
suppressive actions (Angell et al., 2000). Expression 
of NDUFA13 is induced by IFNB1/IFN-beta 
combined with all-trans-retinoic acid. 
Transcription 
The NDUFA gene is characterized by 7 transcripts. 
Three are protein coding transcripts. The transcribed 
mRNA of NDUFA13 gene has 557 bp 
(NM_015965). RNA is expressed in all tissues. Two 
other transcripts are protein coding, one with 120 aa 
and another with 150 aa. Two transcripts are 
nonsense mediated decay and two other retain an 
intron, none of these 4 coding for proteins. 
Transcripts originating from an upstream promoter 
and capable of expressing a protein with a longer N-
terminus have been found, but their biological 
validity has not been determined. (Provided by 
RefSeq, Oct 2009). 
Protein 
Note 
Protein class: disease related genes, mitochondrial 
proteins, predicted membrane proteins. 
Description 
The human NDUFA13 gene encodes for a 16KDa 
protein and 144 aminoacids, purified from 
mitochondria.  
It was first identified as a novel cell death-regulatory 
gene whose inactivation confers growth advantage to 
cells in the presence of IFN/RA (Angell et al., 2000).  
This protein has a modified residue at position 2, an 
alanine that can be acetylated.  
The transmembrane portion of NDUFA13 protein 
encompasses aminoacids at positions 30 to 51, being 
22 residues long, and has a helical shape.  
The 43 aa region consisting of residues 102 to 144, 
is important for inducing cell death. 
Translation (144 aa) 
Amino acids: 144. Molecular weight: 16KD. The 
NDUFA13 gene encodes for a protein that belongs 
to the family of NADH dehydrogenase ubiquitone 1 
alpha subcomplex 13. 
Expression 
Widely expressed with highest expression in heart, 
skeletal muscle, liver, kidney and placenta. (Angell 
et al., 2000) Ubiquitous cytoplasmatic expression 
with a granular pattern. Membrane. 
Localisation 
Mitochondria inner membrane, Single-pass 
membrane protein, Matrix side, Nucleus. (UniProt 
Q9P0J0). 
 
Diagram of the NDUFA13 protein. Numbers indicate amino acids. The box inside represents the transmembrane domain (TM). 
The domains indicated by the blue key represent sequences for mitochondrial targeting, maintenance of Δψm, and enhancing 
assembly. 
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Function 
Molecular function: catalytic - oxiredutase activity - 
and it is involved in metabolic processes and 
biological regulation. 
NDUFA13 was described in 2004 as a gene product 
with a specific role in IFN-RA-induced cell death, as 
a functional component of mitochondrial complex I 
and as being essential for early embryonic 
development (Huang et al., 2004). 
Cell death regulatory protein that promotes 
apoptosis, is a negative regulator of cell growth, and 
it is involved in mitochondrial metabolism (Angell 
et al., 2000; Lufei et al., 2003). 
Accessory subunit of the mitochondrial membrane 
respiratory chain NADH dehydrogenase (Complex 
I). Involved in the interferon/all-trans-retinoic acid 
(IFN/RA) induced cell death, which is inhibited by 
interaction with viral IRF1. Prevents the 
transactivation of STAT3 target genes (Lufei et al., 
2003; Zhang et al., 2003). 
Diseases associated with NDUFA13 include thyroid 
Hürthle cell carcinoma, and kidney cancer. GO 
annotations related to this gene include NADH 
dehydrogenase activity and NADH dehydrogenase 
(ubiquinone) activity. 
Homology 
NDUFA13 score.  
There are still 120 uncharacterized proteins in 
different species including Homo sapiens, with 
homologies varying from 28% to 100% (Homo 
sapiens).  
Nine predicted proteins with homologies between 
40% and 52% have also been identified in different  
 
species (B2014110593WH1M8NCV) 
Mutations 
Loss of expression and occurrence of mutations in 
the NDUFA13 gene in a variety of primary human 
cancers-lung, kidney, prostate, thyroid, ovary, colon, 
esophagus and brain (Alchanati et al., 2006; Máximo 
et al., 2008; Zhou et al., 2009; Fan et al., 2012) - have 
been described, indicating its potential role as tumor 
suppressor.  
Depletion or overexpression of NDUFA13 promotes 
and suppresses, respectively, tumor growth (Angell 
et al., 2000; Máximo et al., 2008; Huang et al., 2010).  
Levels of expression of NDUFA13 are a good 
prognostic marker for colorectal cancer (Hao et al., 
2015) and loss of expression correlate with 
malignancy in Hürthle cell tumours (Donatini et al., 
2015). 
Germinal 
One germline missense mutation of NDUFA13 has 
been identified in one patient with apparently 
sporadic Hürthle cell carcinoma: G264C substitution 
in exon 1 (Máximo et al., 2005). 
Somatic 
Three missense mutations have been identified in 
three out of 20 cases of sporadic Hürthle cell 
carcinomas: a C77T and a A247G in exon 1, and a 
G593C in exon 5 (Máximo et al., 2005).   
Three somatic mutations of NDUFA13 gene have 
been identified in a set of primary head and neck 
tumors (Nallar et al., 2013).  
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Wild-type NDUFA13 suppresses cellular 
transformation by a constitutively active form of 
STAT3, whereas tumor-derived mutants (L71P, 
L91P and A95T) significantly lost their ability to 
associate with STAT3, block gene expression and 
suppress cell transformation and tumor growth in 
vivo. 
These three mutants have also lost their capacity to 
prevent metastasis. 
Implicated in 
Various cancers, arthritis and mouse 
embryo development and 
implantation. 
Disease 
Renal Cell Carcinomas (RCC), inflammatory bowel 
diseases, Kaposi sarcoma, Hürthle cell carcinomas, 
lung cancer, hepatocellular carcinoma, colorectal 
cancer (CRC), prostate carcinoma, cervical 
carcinoma, breast carcinomas, head and neck 
squamous cell carcinoma. 
Prognosis 
NDUFA13 mRNA and protein expression are 
significantly lower in colorectal cancer than in 
normal tissues.  
It is suggested that low NDUFA13 expression is 
closely associated with colorectal cancer progression 
and might be a very promising prognostic biomarker 
for CRC patients (Hao et al., 2015).  
Moreover, in breast cancers, nonexpression of 
NDUFA13 is significantly associated with lymph 
node metastasis, advanced tumor-node-metastasis 
stage, triple-negative which is a mark of bad 
prognosis (Zhou et al., 2013).  
Embryo development and 
implantation 
The expression of NDUFA13 in mouse 
preimplantation embryos changes at different 
developmental phases suggesting an important role 
during embryonic development (Cui et al., 2012). 
Other authors have seen that downregulation of 
NDUFA13 affects mouse oocyte viability, 
maturation and embryo development and 
implantation (Chao et al., 2015). 
Thyroid cancer 
Somatic and germline mutations, 15% and 5%, 
respectively, in NDUFA13, were described in 
Hürthle cell tumors of the thyroid (Máximo et al., 
2005). These mutations were described as the first 
nuclear gene mutations specific to Hürthle cell 
tumors and it was proposed that such mutations may 
be involved in the genesis of sporadic as well as 
familial Hürthle cell tumors through the dual 
function of NDUFA13 in mitochondria metabolism 
and cell death. 
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Renal cell carcinoma 
NDUFA13 expression is lost or severely decreased 
in primary RCC (Alchanati et al., 2006). The 
presence of NDUFA13 protein was evaluated by 
Western blot in 11 cases of RCC and it was absent, 
weakly or moderately present in 4, 6 and 1 cases, 
respectively, compared with normal counterpart 
(Alchanati et al., 2006). The pattern of mRNA 
expression correlated with the level of protein 
expression by Western blot analysis. In the same 
study, an immunostaining evaluation showed intense 
nuclear membrane and cytoplasmic staining in 
proximal tubular epithelium in normal kidney, 
whereas NDUFA13 expression was absent in 93% of 
the cases. Downregulation of NDUFA13 is 
associated with enhanced cell proliferation which is 
proposed to act via uninhibited STAT3 regulatory 
pathway (Alchanati et al., 2006). 
Prostate cancer 
NDUFA13 protein expression is not significantly 
decreased in prostate cancer. Loss of NDUFA13 
staining by immunohistochemistry was found in 
only 2 out of 17 prostate carcinomas (Alchanati et 
al., 2006). 
Kaposi's sarcoma 
NDUFA13 inhibits INF/retinoic acid-induced cell 
death (Seo et al., 2002). 
Lung cancer 
There is a negative correlation between the 
expression level of NDUFA13 and the stage of the 
primary lesion of non-small cell lung carcinomas 
(NSCLC). Downregulation of NDUFA13 was 
described in NSCLC stages III-IV compared to 
stages I-II (Fan et al., 2012). GRIM-19 is mainly 
located in the cytoplasm in lung inflammation 
tissues, but located in the nucleus in lung cancer 
tissues (Fan et al., 2012). 
Hepatocellular carcinoma 
Expression levels of NDUFA13 are significantly 
lower in hepatocellular carcinoma patients with 
deteriorating differentiation states, hepatic capsule 
invasion and microvascular invasion (Hao et al., 
2012). 
Gliomas 
Gliomas express NDUFA13 at low levels and this 
plays a major role in tumorigenesis of the brain. 
NDUFA13 mRNA and protein levels are 
significantly lower in gliomas than in control brain 
tissues. NDUFA13 expression levels negatively 
correlates with malignancy of the gliomas (Zhang et 
al., 2011). 
Cervical cancer 
Zhou et al. have shown that reduction of the levels 
of NDUFA13 protein occurs in primary cervical 
cancers, and is associated with hyperactivation of 
STAT3 (Zhou et al., 2009; Chen et al., 2015). 
Breast cancer 
Nonexpression of NDUFA13 is significantly 
associated with lymph node metastasis, advanced 
tumor-node-metastasis stage, triple-negative 
phenotype and low NDUFA13 expression is 
correlated with STAT3 overexpression (Zhou et al., 
2013). 
Colorectal cancer 
NDUFA13 shows low or absent expression in 
colorectal carcinomas. mRNA and protein 
expression are lower in colorectal carcinoma than in 
normal tissues (Hao et al., 2015). 
Head and neck squamous cell 
carcinoma 
Decreased expression of NDUFA13 due to 
hypermethylation is correlated with cell proliferation 
in head and neck squamous cell carcinoma (Zhang et 
al., 2015). 
Inflamatory bowel disease 
NDUFA13 expression is decreased in inflamed 
mucosa of patients with inflammatory bowel disease 
(Barnich et al., 2005). 
Bladder urothelium 
NDUFA13 protein expression is not significantly 
decreased in bladder tumors. Loss of NDUFA13 
staining by immunohistochemistry was found in 
only 1 of 6 transitional cell carcinomas of the renal 
pelvis (Alchanati et al., 2006). 
Arthritis 
NDUFA13 attenuates murine autoimmune arthritis 
(Moon et al., 2014). 
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